Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Immuron Limited is a biotechnology business based in the US. Immuron shares (IMRN) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Social investors
| Latest market close | $4.85 |
|---|---|
| 52-week range | $4.63 - $11.94 |
| 50-day moving average | $4.85 |
| 200-day moving average | $5.80 |
| Wall St. target price | $6.41 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.68 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.85 from 2021-05-28
| 1 week (2021-07-25) | N/A |
|---|---|
| 1 month (2021-07-02) | 4.85 |
| 3 months (2021-05-05) | -9.68% |
| 6 months (2021-02-01) | N/A |
| 1 year (2020-08-01) | N/A |
|---|---|
| 2 years (2019-08-01) | N/A |
| 3 years (2018-08-01) | N/A |
| 5 years (2016-08-01) | N/A |
| Revenue TTM | $982,252 |
|---|---|
| Gross profit TTM | $1.8 million |
| Return on assets TTM | -21.43% |
| Return on equity TTM | -40.38% |
| Profit margin | 0% |
| Book value | $5.04 |
| Market capitalisation | $27.2 million |
TTM: trailing 12 months
There are currently 5,583 Immuron shares held short by investors – that's known as Immuron's "short interest". This figure is 0% down from 5,583 last month.
There are a few different ways that this level of interest in shorting Immuron shares can be evaluated.
Immuron's "short interest ratio" (SIR) is the quantity of Immuron shares currently shorted divided by the average quantity of Immuron shares traded daily (recently around 6068.4782608696). Immuron's SIR currently stands at 0.92. In other words for every 100,000 Immuron shares traded daily on the market, roughly 920 shares are currently held short.
However Immuron's short interest can also be evaluated against the total number of Immuron shares, or, against the total number of tradable Immuron shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immuron's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Immuron shares in existence, roughly 0 shares are currently held short) or 0.001% of the tradable shares (for every 100,000 tradable Immuron shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immuron.
Find out more about how you can short Immuron stock.
We're not expecting Immuron to pay a dividend over the next 12 months.
Over the last 12 months, Immuron's shares have ranged in value from as little as $4.63 up to $11.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immuron's is 1.7759. This would suggest that Immuron's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia. .
Everything we know about the Chobani IPO, plus information on how to buy in.
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
